Mizoguchi K
Department of Neurology, National Shizuoka Hospital, Japan.
Neurol Res. 1998 Oct;20(7):617-24. doi: 10.1080/01616412.1998.11740573.
The correlation between the activities of anti-GQ1b IgG antibodies in sera of patients with Miller Fisher syndrome and their clinical manifestations was investigated. The clinical severity was analyzed for 16 patients by scoring their symptoms during the peak of the clinical course and 4 weeks after onset. Serum samples were obtained from all the patients within the first 2 weeks of onset and from 12 of them 4 weeks after onset. Samples were immunostained by TLC after which antibody activities were measured by the ELISA. Anti-GQ1b IgG antibody activities reflect the severity of the patients' symptoms, especially ophthalmoplegia. Lessening of symptoms, expressed by the difference in MFS severity scores of the two tests, occurred with the marked decrease in antibodies. Results of cerebrospinal fluid and nerve conduction studies, performed during the first 2 weeks, showed no fluctuation with changes in the clinical symptoms or antibody activities.
研究了米勒-费希尔综合征患者血清中抗GQ1b IgG抗体活性与其临床表现之间的相关性。通过对16例患者在临床病程高峰期及发病后4周的症状进行评分来分析临床严重程度。在发病的前2周内采集所有患者的血清样本，发病后4周采集其中12例患者的血清样本。样本经薄层层析免疫染色后，采用酶联免疫吸附测定法测量抗体活性。抗GQ1b IgG抗体活性反映了患者症状的严重程度，尤其是眼肌麻痹。两次检测的MFS严重程度评分差异所体现的症状减轻与抗体显著减少有关。在发病的前2周内进行的脑脊液和神经传导研究结果显示，其未随临床症状或抗体活性的变化而波动。
